In a bid to streamline its focus towards its core business, Bristol-Myers Squibb has decided to divest its consumer health business, Union Pharmacologique Scientifique Appliquee (UPSA), following a strategic review announced in June 2018. Japanese consumer health company Taisho Pharmaceutical Holding group has offered to acquire UPSA for a value of US$1.6 B. Should the offer be accepted, the transaction is expected to complete in the first half of 2019 and will give Taisho a portfolio of well-established brands, a strong manufacturing platform and a greater geographic presence.